Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts.
Identifieur interne : 000E41 ( Main/Exploration ); précédent : 000E40; suivant : 000E42Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts.
Auteurs : Karun Neupane ; Zahoor Ahmed ; Hira Pervez ; Rabia Ashraf ; Aneela Majeed [États-Unis]Source :
- Cureus [ 2168-8184 ] ; 2020.
Abstract
Coronavirus disease-2019 (COVID-19), first reported in China during December of 2019, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection later spread very rapidly around the globe with over 8,708,008 cases reported, including more than 461,715 deaths reported across at least 216 countries by June 20, 2020. It was declared as a global pandemic by the World Health Organization (WHO) on March 11, 2020. With the rapidly increasing number of positive cases and deaths, there is a dire need for effective treatment. An urgent unmet need led to the planning and opening of multiple drug development trials for treatment and vaccine development. In this article, we have compiled comprehensive data on many candidate drugs such as remdesivir, favipiravir, ribavirin, umifenovir, arbidol, lopinavir, ritonavir, baricitinib, hydroxychloroquine, nitazoxanide, azithromycin, baloxavir, oseltamivir, losartan, and tocilizumab. We have tabulated available data on various clinical trials testing various aspects of COVID-19 therapeutics.
DOI: 10.7759/cureus.8845
PubMed: 32754388
PubMed Central: PMC7386097
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts.</title><author><name sortKey="Neupane, Karun" sort="Neupane, Karun" uniqKey="Neupane K" first="Karun" last="Neupane">Karun Neupane</name><affiliation><nlm:affiliation>Internal Medicine, Manipal College of Medical Sciences, Pokhara, NPL.</nlm:affiliation><wicri:noCountry code="subField">NPL</wicri:noCountry></affiliation></author><author><name sortKey="Ahmed, Zahoor" sort="Ahmed, Zahoor" uniqKey="Ahmed Z" first="Zahoor" last="Ahmed">Zahoor Ahmed</name><affiliation><nlm:affiliation>Internal Medicine, King Edward Medical University, Mayo Hospital, Lahore, PAK.</nlm:affiliation><wicri:noCountry code="subField">PAK</wicri:noCountry></affiliation></author><author><name sortKey="Pervez, Hira" sort="Pervez, Hira" uniqKey="Pervez H" first="Hira" last="Pervez">Hira Pervez</name><affiliation><nlm:affiliation>Internal Medicine/Cardiology, Dow University of Health Sciences, Karachi, PAK.</nlm:affiliation><wicri:noCountry code="subField">PAK</wicri:noCountry></affiliation></author><author><name sortKey="Ashraf, Rabia" sort="Ashraf, Rabia" uniqKey="Ashraf R" first="Rabia" last="Ashraf">Rabia Ashraf</name><affiliation><nlm:affiliation>Internal Medicine, King Edward Medical University, Lahore, PAK.</nlm:affiliation><wicri:noCountry code="subField">PAK</wicri:noCountry></affiliation></author><author><name sortKey="Majeed, Aneela" sort="Majeed, Aneela" uniqKey="Majeed A" first="Aneela" last="Majeed">Aneela Majeed</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases, Cleveland Clinic, Cleveland, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Diseases, Cleveland Clinic, Cleveland</wicri:regionArea><wicri:noRegion>Cleveland</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32754388</idno><idno type="pmid">32754388</idno><idno type="doi">10.7759/cureus.8845</idno><idno type="pmc">PMC7386097</idno><idno type="wicri:Area/Main/Corpus">000F80</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F80</idno><idno type="wicri:Area/Main/Curation">000F80</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000F80</idno><idno type="wicri:Area/Main/Exploration">000F80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts.</title><author><name sortKey="Neupane, Karun" sort="Neupane, Karun" uniqKey="Neupane K" first="Karun" last="Neupane">Karun Neupane</name><affiliation><nlm:affiliation>Internal Medicine, Manipal College of Medical Sciences, Pokhara, NPL.</nlm:affiliation><wicri:noCountry code="subField">NPL</wicri:noCountry></affiliation></author><author><name sortKey="Ahmed, Zahoor" sort="Ahmed, Zahoor" uniqKey="Ahmed Z" first="Zahoor" last="Ahmed">Zahoor Ahmed</name><affiliation><nlm:affiliation>Internal Medicine, King Edward Medical University, Mayo Hospital, Lahore, PAK.</nlm:affiliation><wicri:noCountry code="subField">PAK</wicri:noCountry></affiliation></author><author><name sortKey="Pervez, Hira" sort="Pervez, Hira" uniqKey="Pervez H" first="Hira" last="Pervez">Hira Pervez</name><affiliation><nlm:affiliation>Internal Medicine/Cardiology, Dow University of Health Sciences, Karachi, PAK.</nlm:affiliation><wicri:noCountry code="subField">PAK</wicri:noCountry></affiliation></author><author><name sortKey="Ashraf, Rabia" sort="Ashraf, Rabia" uniqKey="Ashraf R" first="Rabia" last="Ashraf">Rabia Ashraf</name><affiliation><nlm:affiliation>Internal Medicine, King Edward Medical University, Lahore, PAK.</nlm:affiliation><wicri:noCountry code="subField">PAK</wicri:noCountry></affiliation></author><author><name sortKey="Majeed, Aneela" sort="Majeed, Aneela" uniqKey="Majeed A" first="Aneela" last="Majeed">Aneela Majeed</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases, Cleveland Clinic, Cleveland, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Infectious Diseases, Cleveland Clinic, Cleveland</wicri:regionArea><wicri:noRegion>Cleveland</wicri:noRegion></affiliation></author></analytic><series><title level="j">Cureus</title><idno type="ISSN">2168-8184</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease-2019 (COVID-19), first reported in China during December of 2019, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection later spread very rapidly around the globe with over 8,708,008 cases reported, including more than 461,715 deaths reported across at least 216 countries by June 20, 2020. It was declared as a global pandemic by the World Health Organization (WHO) on March 11, 2020. With the rapidly increasing number of positive cases and deaths, there is a dire need for effective treatment. An urgent unmet need led to the planning and opening of multiple drug development trials for treatment and vaccine development. In this article, we have compiled comprehensive data on many candidate drugs such as remdesivir, favipiravir, ribavirin, umifenovir, arbidol, lopinavir, ritonavir, baricitinib, hydroxychloroquine, nitazoxanide, azithromycin, baloxavir, oseltamivir, losartan, and tocilizumab. We have tabulated available data on various clinical trials testing various aspects of COVID-19 therapeutics.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32754388</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts.</ArticleTitle><Pagination><MedlinePgn>e8845</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.8845</ELocationID><Abstract><AbstractText>Coronavirus disease-2019 (COVID-19), first reported in China during December of 2019, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection later spread very rapidly around the globe with over 8,708,008 cases reported, including more than 461,715 deaths reported across at least 216 countries by June 20, 2020. It was declared as a global pandemic by the World Health Organization (WHO) on March 11, 2020. With the rapidly increasing number of positive cases and deaths, there is a dire need for effective treatment. An urgent unmet need led to the planning and opening of multiple drug development trials for treatment and vaccine development. In this article, we have compiled comprehensive data on many candidate drugs such as remdesivir, favipiravir, ribavirin, umifenovir, arbidol, lopinavir, ritonavir, baricitinib, hydroxychloroquine, nitazoxanide, azithromycin, baloxavir, oseltamivir, losartan, and tocilizumab. We have tabulated available data on various clinical trials testing various aspects of COVID-19 therapeutics.</AbstractText><CopyrightInformation>Copyright © 2020, Neupane et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neupane</LastName><ForeName>Karun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Internal Medicine, Manipal College of Medical Sciences, Pokhara, NPL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Zahoor</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Internal Medicine, King Edward Medical University, Mayo Hospital, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pervez</LastName><ForeName>Hira</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Internal Medicine/Cardiology, Dow University of Health Sciences, Karachi, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashraf</LastName><ForeName>Rabia</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Internal Medicine, King Edward Medical University, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majeed</LastName><ForeName>Aneela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Diseases, Cleveland Clinic, Cleveland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">sars-cov-2</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32754388</ArticleId><ArticleId IdType="doi">10.7759/cureus.8845</ArticleId><ArticleId IdType="pmc">PMC7386097</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Virol. 2004 Dec;31(4):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15494274</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2020 Jan;25(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Feb;578(7795):347-348</Citation><ArticleIdList><ArticleId IdType="pubmed">32071447</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):e30-e31</Citation><ArticleIdList><ArticleId IdType="pubmed">32032529</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102</Citation><ArticleIdList><ArticleId IdType="pubmed">32258207</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776</Citation><ArticleIdList><ArticleId IdType="pubmed">32054787</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2013 Dec;100(3):662-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24161512</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e21</Citation><ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Dev Res. 2020 Aug;81(5):537-540</Citation><ArticleIdList><ArticleId IdType="pubmed">32129518</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Jul;87(14):8017-28</Citation><ArticleIdList><ArticleId IdType="pubmed">23678171</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Jul 31;349(5):507-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12890854</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Cent Sci. 2020 Mar 25;6(3):315-331</Citation><ArticleIdList><ArticleId IdType="pubmed">32226821</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ecancermedicalscience. 2020 Mar 30;14:1023</Citation><ArticleIdList><ArticleId IdType="pubmed">32256706</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 1999 Jan 25;159(2):167-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9927100</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Jun;178:104787</Citation><ArticleIdList><ArticleId IdType="pubmed">32251768</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):206-214</Citation><ArticleIdList><ArticleId IdType="pubmed">28003465</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Ther Pat. 2013 Oct;23(10):1337-48</Citation><ArticleIdList><ArticleId IdType="pubmed">23905913</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation><ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151</Citation><ArticleIdList><ArticleId IdType="pubmed">32064853</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975</Citation><ArticleIdList><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jun;92(6):683-687</Citation><ArticleIdList><ArticleId IdType="pubmed">32162699</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation><ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Ahmed, Zahoor" sort="Ahmed, Zahoor" uniqKey="Ahmed Z" first="Zahoor" last="Ahmed">Zahoor Ahmed</name><name sortKey="Ashraf, Rabia" sort="Ashraf, Rabia" uniqKey="Ashraf R" first="Rabia" last="Ashraf">Rabia Ashraf</name><name sortKey="Neupane, Karun" sort="Neupane, Karun" uniqKey="Neupane K" first="Karun" last="Neupane">Karun Neupane</name><name sortKey="Pervez, Hira" sort="Pervez, Hira" uniqKey="Pervez H" first="Hira" last="Pervez">Hira Pervez</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Majeed, Aneela" sort="Majeed, Aneela" uniqKey="Majeed A" first="Aneela" last="Majeed">Aneela Majeed</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32754388
|texte= Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32754388" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |